saffron and metabolic syndrome, general, positive, negative an cognitive symptomes in schizophrenic patients treated with olanzapin.
Phase 2
- Conditions
- Schizophrenia.Schizophrenia
- Registration Number
- IRCT2013020312351N1
- Lead Sponsor
- niversity of Social Welfare and Rehabilitation Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Male
- Target Recruitment
- 44
Inclusion Criteria
diagnosis of schizophrenia according to DSM-IV-TR criteria; clinical stability without acute phase; no acute medical problem; no coronary heart disease or metabolic syndrome; no neurological disease; no substance abuse or dependency accept nicotine; no usage of anti platelets drugs or ASA or herbal medicines; not being mental retarded; no special slimming or obesity diets
Exclusion criteria: Any unwanted side effects that interfere with standard treatment or cause patient refusal of treatment; Need to change olanzapine in the course of treatment for any reason
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Metabolic Syndrome Parameters (FBS, TGL,HDL, BP, Waist circumstance). Timepoint: weeks 2,6,12. Method of measurement: Blood Sample Test and Physical Examination.
- Secondary Outcome Measures
Name Time Method Changes in Insuline Resistance, General, Positive and Negative and Cognitive Symptomes. Timepoint: Insuline Resistence: week 0 and 12, others weeks 0, 6 and 12. Method of measurement: HOMA-IR, BPRS, MMSE.